Developer docs
API playgroundTry for free, no card

Search company profiles

Digital Infuzion

Full company profile

uuid0008udb

Namestring
Digital Infuzion
Legal namestring
Digital Infuzion, LLC
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Digital Infuzion, LLC is a privately held federal health informatics and IT services company founded in 1999 by Hemant Virkar, a former NIH technical lead, and headquartered in Rockville, Maryland. The company designs and operates custom informatics solutions for federal health and civilian agencies (notably NIH institutes including NIAID, NCI, NIA, and NIEHS; CMS; SEC; DTRA; and DHS), commercial pharmaceutical and biotech sponsors, non-profit research institutions, and standards bodies such as CDISC. Its core offerings combine two proprietary product platforms — GeneBrain®, an analytics and visualization platform built on patented self-optimizing machine learning (US8386401) and big-data visualization (US8812274) — and the N of 1 Health Research Platform, a cloud-based SaaS for patient registries, observational studies, and electronic patient-reported outcomes, with a specialized RegistryNXT! configuration for pharma rare-disease programs.

The underlying technology stack spans AI/ML (predictive analytics, NLP, generative AI via LLM fine-tuning and Retrieval Augmented AI on Microsoft Azure OpenAI, computer vision, and anomaly detection), cloud-native development on AWS and Azure using Agile DevSecOps, and integration with EMR/EHR systems, Medidata RAVE, CDISC standards, and wearables. Digital Infuzion also holds four ISO certifications (9001, 20000-1, 27001, 22301), CMMI Level 3 (Development and Services), and compliance postures covering HIPAA, GDPR, and 21 CFR Part 11.

The business model blends three revenue streams. The dominant stream is professional services delivered through federal IDIQ vehicles — CIO-SP3 (Small Business, 8(a), and Large Business via the INDUS-led HIITS CTA), the CMS SPARC contract (up to $25B shared ceiling, base period 2017-2022 with options to 2027), and GSA Schedule #47QTCA19D00FW through July 2029 — billed under T&M, FFP, and CPFF arrangements. A secondary stream is commercial healthcare/pharma IT consulting (Sanofi Genzyme, EMD Serono, Alexion, Agios, Alnylam, Sarepta, Ultragenyx and others). A third, still emerging stream is SaaS subscription revenue from the N of 1 platform, with pricing quote-based and annual billing. Go-to-market combines enterprise field sales via capture management and program leadership, channel partner teaming (INDUS, Armedia, Mentor-Protégé JVs Aspire, Digital Edge, Tera Fuzion), and federal procurement portal presence (GSA Advantage!, eBuy).

Short descriptiontext

Digital Infuzion is a privately held federal health informatics firm that builds AI-enabled clinical research and data analytics platforms (GeneBrain®, N of 1) for NIH, CMS, SEC, DTRA, DHS, pharmaceutical sponsors, and academic medical centers, delivered via CIO-SP3, SPARC, and GSA contract vehicles.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersRockville, United States
HQ citystring
Rockville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical informatics services, biomedical data analytics, patient registry software, health IT consulting, federal health IT
Industry4 codes
PRIMARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLACAOAJ
Site & Investigator Platforms (Site Payments, Feasibility, Activation)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAGAOAB
Data Management, Biostatistics & Statistical Programming FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)
SECONDARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Computer Systems Design and Related Services54151
  • Other Scientific and Technical Consulting Services54169
SIC code2 codes
  • Services-Health Services8000
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Research Informatics
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Federal Government IT Services
TypeProfessional Services
Description

Professional IT services delivered to federal agencies through multiple IDIQ contract vehicles including CIO-SP3 (Small Business, 8(a), Large Business), SPARC (CMS), and GSA Schedule. Services include software engineering, clinical informatics, bioinformatics, health IT, cloud services, data science, cybersecurity, and enterprise application services. Revenue generated through time-and-materials (T&M), firm-fixed-price (FFP), cost-plus-fixed-fee (CPFF), and various other contract types.

digitalinfuzion.com
2Commercial Healthcare IT Services
TypeProfessional Services
Description

IT consulting and implementation services for commercial healthcare organizations, pharmaceutical companies, biotech firms, and non-profit health research institutions. Services include digital transformation, clinical research systems, data analytics, and regulatory compliance solutions.

digitalinfuzion.com
3N of 1 Health Research Platform (SaaS)
TypeSubscription Recurring
Description

The N of 1 Platform is offered as a cloud-based SaaS disease management solution providing electronic patient reported outcomes, analytics, EDC integration, and patient registry capabilities. Customers include pharmaceutical companies, biotech companies, patient advocacy/non-profit groups, and academic organizations implementing Patient Registries and Observational Studies in the rare disease domain.

digitalinfuzion.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details4 tiers
1GSA Schedule IT Services - Cloud and IT Professional Services
ModelOtherBilling cadenceMulti-year contract
Notes

Contract #47QTCA19D00FW. Services available under SINs: 518210C (Cloud/Cloud IT Professional Services), 54151 (Software Maintenance), 54151S (IT Professional Services), 54151HEAL (Health IT Services). Task order types: FFP, T&M. Contract expires July 2029.

digitalinfuzion.com
2SPARC Contract - CMS Strategic Partners Acquisition Readiness Contract
ModelOtherBilling cadenceMulti-year contract
Notes

MA-IDIQ performance-based contract for CMS and HHS. Contract types: CPFF, CPAF, CPI, FFP, FFPAF, FPI, T&M, LH. Min/Max: $1,000 to $25 Billion over contract life. Base period: Feb 2017 - Feb 2022, Optional: Feb 2022 - Feb 2027. Competition required for task orders.

digitalinfuzion.com
3CIO-SP3 8(a) - HHSN316201200077W
ModelOtherBilling cadenceMulti-year contract
Notes

Ten task areas covering IT services for biomedical research, CIO support, imaging, outsourcing, IT operations, integration services, critical infrastructure protection, digital government, ERP, and software development. Prompt payment terms: Net 30.

digitalinfuzion.com
4N of 1 Health Research Platform SaaS Subscription
ModelSubscriptionBilling cadenceAnnual
Notes

Request Preliminary Quote available through online form. Platform provides ePRO, analytics, EDC integration, patient registry, mobile health behavior change capabilities. Used by pharmaceutical companies, biotech, patient advocacy groups, and academic organizations for rare disease registries and observational studies.

digitalinfuzion.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1GeneBrain®
Description

A data analytics solution that allows researchers and clinicians to gain at-a-glance insights into complex biological data using 3D visualizations and patented self-optimizing learning machines.

digitalinfuzion.com
+1 more record
Core offering1 text field

Digital Infuzion delivers clinical informatics services and proprietary software platforms to federal health agencies, defense agencies, pharmaceutical sponsors, and non-profit/academic medical centers. Its core commercial products are the GeneBrain® data analytics platform (with patented self-optimizing machine learning and 3D visualization) and the N of 1 Health Research Platform (a cloud-based SaaS for patient registries, ePRO, and observational studies). The majority of revenue is generated through federal IT services delivered under CIO-SP3, SPARC, and GSA Schedule contract vehicles using T&M, FFP, and CPFF task orders.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • N of 1 Platform achieves 94%+ predictive accuracy in muscle tissue analysis using GeneBrain®
+4 more records
Product overview1 text field

Digital Infuzion offers a portfolio of proprietary products centered on two core platforms: GeneBrain® and the N of 1 Health Research Platform. GeneBrain® is a data analytics solution that applies patented self-optimizing machine learning algorithms and 3D visualization technology to complex biological and clinical data, enabling researchers to identify predictive biomarkers and discover patterns across large datasets. The N of 1 Health Research Platform is a cloud-based SaaS disease management and patient registry solution that integrates electronic patient-reported outcomes (ePRO), clinical data capture (EDC), and EMR interoperability to support observational research, rare disease registries, and patient-centric outcomes studies. The company also holds two foundational patents — Machine Learning Methods (US8386401) for automated predictive analytics and Visualizing Big Data (US8812274) for 3D data visualization — which underpin capabilities across both platforms. RegistryNXT! is a specialized configuration of the N of 1 platform built for pharmaceutical rare disease registries. Together, these products form an integrated ecosystem for translational research, from molecular data analysis to patient-level clinical outcomes.

Product and service3 records
1GeneBrain®
CategoryData analytics platform
Description

A proprietary data analytics solution that models large volumes of complex biological data for monitoring, classification of samples, repository querying, biomarker identification, and hypothesis refinement and validation. Uses patented self-optimizing learning machines and 3D visualizations that make biological discoveries intuitive for biomedical researchers, clinical scientists, and pharmaceutical sponsors.

2N of 1 Health Research Platform
CategoryPatient registry and disease management SaaS
Description

A real-time, patient-centric, web-based, mobile-friendly SaaS disease management and analytics platform for observational studies and patient registries. Features include electronic patient reported outcomes (ePRO), EDC and EMR integration, patient registry capabilities, GDPR/GCP/21 CFR Part 11/HIPAA compliance, and integration with wearables and biometric devices. Customers include pharmaceutical companies, biotech firms, patient advocacy groups, and academic organizations in the rare disease domain.

3RegistryNXT! Platform
CategoryPharmaceutical rare disease registry solution
Description

A specialized implementation of the N of 1 Health Research Platform for managing rare disease registries, including for Sanofi Genzyme. Features CDISC-compliant data interchange, integration with Medidata's RAVE, role-based disease management, and regulatory reporting capabilities for pharmaceutical sponsors.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2012-01-01
Description

INDUS Corporation is the lead and contract holder for the CIO-SP3 Large Business GWAC through the HIITS CTA. Digital Infuzion is a strategic partner in this Contractor Team Arrangement fulfilling NITAAC's vision for CIO-SP3 GWAC serving NIH and all federal agencies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2012-01-01
Description

Armedia participates as CTA partner in both CIO-SP3 Large Business (HIITS CTA with INDUS) and CIO-SP3 8(a) Business (CIO Source CTA with Digital Infuzion). Armedia provides technology integration and data management capabilities for federal health IT contracts.

3Aspire Informatics
Strategic tierMinorTypeOthers
Description

8(a) Joint Venture partner in Digital Infuzion's Mentor-Protégé Program. Aspire Informatics participates as a protégé organization benefiting from Digital Infuzion's domain expertise, business reputation, and resources.

digitalinfuzion.com
Strategic tierMinorTypeOthers
Description

WOSB (Women-Owned Small Business) Joint Venture partner in Digital Infuzion's Mentor-Protégé Program. Digital Edge participates as a protégé gaining access to Digital Infuzion's corporate capabilities while expanding market reach.

5Tera Fuzion
Strategic tierMinorTypeOthers
Description

SDVOSB (Service-Disabled Veteran-Owned Small Business) Joint Venture partner in Digital Infuzion's Mentor-Protégé Program. Tera Fuzion collaborates with Digital Infuzion on federal contracting opportunities.

digitalinfuzion.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Carson Associates participates as CTA partner in Digital Infuzion's CIO Source™ arrangement for CIO-SP3 8(a) Business GWAC, providing specialized technical capabilities for federal contracting engagements.

7Partner Ecosystem
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Digital Infuzion maintains a diverse partner ecosystem of small businesses to large organizations with well-known brands to address complex Cloud services, cybersecurity, and data analytics challenges. Partners are assembled per customer requirement to deliver modern transformative solutions.

digitalinfuzion.com
8CDISC (Clinical Data Interchange Standards Consortium)
Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Digital Infuzion serves on the CDISC Industry Advisory Board. The company helps standards organizations do their work by building web-based collaboration environments and providing services to enhance CDISC's business and data management activities. CDISC membership supports the company's healthcare data standardization mission.

digitalinfuzion.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global clinical research services and technology vendor (formerly QuintilesIMS) competing head-to-head with DIFZ's N of 1 platform in rare disease registries, EDC, ePRO, and RWE/observational studies. Much larger commercial pharma focus and global footprint, but a frequent competitor and partner on registry initiatives.

TypeDirect peer
Description

Private clinical research and biostatistics services organization serving NIH institutes (NIAID, NCI, NEI), FDA, and biopharma with patient registries, EDC, and data coordination. Highly comparable: similar size, biomedical research focus, founder-friendly federal culture, and DIFZ's CHRO Jennifer Fairfax previously served as CHRO at Emmes.

TypeDirect peer
Description

Non-profit research organization with strong federal health research IT practice including data coordination centers, biostatistics, and survey research for NIH, CMS, and HHS. Closely comparable by mission, federal health research focus, and clinical research informatics service mix (DIFZ is even mentioned as a collaborator context).

TypeDirect peer
Description

Public federal health and science IT services company of comparable size, providing digital transformation, clinical research support, and program management to NIH, CDC, DoD, and CMS. Directly comparable on contract vehicles, federal health focus, and biomedical informatics delivery model—DIFZ's CGO Davyd Chung previously served as VP at DLH.

TypeDirect peer
Description

Non-profit research organization with deep federal health research and data analytics practice serving HHS, CMS, NIH, and patient advocacy groups. Comparable on research IT, observational studies, and survey/data coordination for federal health; overlapping on data standards work.

TypeBroad incumbent
Description

Large public consulting firm with a major federal health IT practice (NIH, HHS, CMS, FDA) including health analytics, biosurveillance, and clinical research informatics. Competes with DIFZ on CIO-SP3 task orders and similar large federal health IT procurements but at vastly larger scale and broader capability footprint.

TypeBroad incumbent
Description

Public consulting firm providing digital transformation, health analytics, and IT modernization to HHS, CMS, NIH, and CDC. Competes on overlapping federal health IT/RWE/biostatistics task orders with DIFZ but at significantly larger scale and broader commercial/government portfolio.

TypeBroad incumbent
Description

Large public systems integrator with a substantial federal health and life sciences practice (NIH, CMS, FDA, DoD health) offering informatics, clinical research support, and biosurveillance. Competes with DIFZ on CIO-SP3 and SPARC task orders at a vastly larger scale.

TypeEmerging player
Description

Specialty ePRO/EDC and clinical trial technology providers focused on rare disease registries and patient-centric studies. Comparable to N of 1 in product category, customer segment (biotech/non-profit disease foundations), and SaaS delivery model—representing real potential share competition in DIFZ's rare disease sweet spot.

TypeDirect peer
Description

Non-profit research institute with a large federal health research IT and biostatistics practice serving NIH, FDA, and global health agencies. Comparable in clinical research informatics, patient registries, and federal contracting model—DIFZ is a vendor to RTI for the PopGen typhoid vaccine study using GeneBrain®.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers24 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI capability13 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Digital Infuzion

Clinical Research Informaticsdigitalinfuzion.com

Digital Infuzion is a privately held federal health informatics firm that builds AI-enabled clinical research and data analytics platforms (GeneBrain®, N of 1) for NIH, CMS, SEC, DTRA, DHS, pharmaceutical sponsors, and academic medical centers, delivered via CIO-SP3, SPARC, and GSA contract vehicles.

What Digital Infuzion does

Digital Infuzion, LLC is a privately held federal health informatics and IT services company founded in 1999 by Hemant Virkar, a former NIH technical lead, and headquartered in Rockville, Maryland. The company designs and operates custom informatics solutions for federal health and civilian agencies (notably NIH institutes including NIAID, NCI, NIA, and NIEHS; CMS; SEC; DTRA; and DHS), commercial pharmaceutical and biotech sponsors, non-profit research institutions, and standards bodies such as CDISC. Its core offerings combine two proprietary product platforms — GeneBrain®, an analytics and visualization platform built on patented self-optimizing machine learning (US8386401) and big-data visualization (US8812274) — and the N of 1 Health Research Platform, a cloud-based SaaS for patient registries, observational studies, and electronic patient-reported outcomes, with a specialized RegistryNXT! configuration for pharma rare-disease programs.

The underlying technology stack spans AI/ML (predictive analytics, NLP, generative AI via LLM fine-tuning and Retrieval Augmented AI on Microsoft Azure OpenAI, computer vision, and anomaly detection), cloud-native development on AWS and Azure using Agile DevSecOps, and integration with EMR/EHR systems, Medidata RAVE, CDISC standards, and wearables. Digital Infuzion also holds four ISO certifications (9001, 20000-1, 27001, 22301), CMMI Level 3 (Development and Services), and compliance postures covering HIPAA, GDPR, and 21 CFR Part 11.

The business model blends three revenue streams. The dominant stream is professional services delivered through federal IDIQ vehicles — CIO-SP3 (Small Business, 8(a), and Large Business via the INDUS-led HIITS CTA), the CMS SPARC contract (up to $25B shared ceiling, base period 2017-2022 with options to 2027), and GSA Schedule #47QTCA19D00FW through July 2029 — billed under T&M, FFP, and CPFF arrangements. A secondary stream is commercial healthcare/pharma IT consulting (Sanofi Genzyme, EMD Serono, Alexion, Agios, Alnylam, Sarepta, Ultragenyx and others). A third, still emerging stream is SaaS subscription revenue from the N of 1 platform, with pricing quote-based and annual billing. Go-to-market combines enterprise field sales via capture management and program leadership, channel partner teaming (INDUS, Armedia, Mentor-Protégé JVs Aspire, Digital Edge, Tera Fuzion), and federal procurement portal presence (GSA Advantage!, eBuy).

Digital Infuzion firmographics

Firmographics
Name
Digital Infuzion
Legal name
Digital Infuzion, LLC
Website
https://digitalinfuzion.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
101–250 employees
Short description
Digital Infuzion is a privately held federal health informatics firm that builds AI-enabled clinical research and data analytics platforms (GeneBrain®, N of 1) for NIH, CMS, SEC, DTRA, DHS, pharmaceutical sponsors, and academic medical centers, delivered via CIO-SP3, SPARC, and GSA contract vehicles.
Ownership category
akta.pro rank

Digital Infuzion industry classification

Industry
Product category
Clinical Research Informatics
NAICS
Scientific Research and Development Services (5417), Computer Systems Design and Related Services (54151), Other Scientific and Technical Consulting Services (54169)
SIC
Services-Health Services (8000), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLACAOAJ
Site & Investigator Platforms (Site Payments, Feasibility, Activation)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLAGAOAB
Data Management, Biostatistics & Statistical Programming FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)
SECONDARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)

Keywords

  • Clinical informatics services
  • Biomedical data analytics
  • Patient registry software
  • Health IT consulting
  • Federal health IT

Where Digital Infuzion is headquartered

Location

Headquarters

HQ city
Rockville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Digital Infuzion business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Federal Government IT Services: Professional IT services delivered to federal agencies through multiple IDIQ contract vehicles including CIO-SP3 (Small Business, 8(a), Large Business), SPARC (CMS), and GSA Schedule. Services include software engineering, clinical informatics, bioinformatics, health IT, cloud services, data science, cybersecurity, and enterprise application services. Revenue generated through time-and-materials (T&M), firm-fixed-price (FFP), cost-plus-fixed-fee (CPFF), and various other contract types.
  2. Commercial Healthcare IT Services: IT consulting and implementation services for commercial healthcare organizations, pharmaceutical companies, biotech firms, and non-profit health research institutions. Services include digital transformation, clinical research systems, data analytics, and regulatory compliance solutions.
  3. N of 1 Health Research Platform (SaaS): The N of 1 Platform is offered as a cloud-based SaaS disease management solution providing electronic patient reported outcomes, analytics, EDC integration, and patient registry capabilities. Customers include pharmaceutical companies, biotech companies, patient advocacy/non-profit groups, and academic organizations implementing Patient Registries and Observational Studies in the rare disease domain.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractGSA Schedule IT Services - Cloud and IT Professional Services
OtherMulti-year contractSPARC Contract - CMS Strategic Partners Acquisition Readiness Contract
OtherMulti-year contractCIO-SP3 8(a) - HHSN316201200077W
SubscriptionAnnualN of 1 Health Research Platform SaaS Subscription

Go-to-market motion3 records

Distribution channels6 records

Marketing channels5 records

Digital Infuzion product offering

Product offering

Core offering

Digital Infuzion delivers clinical informatics services and proprietary software platforms to federal health agencies, defense agencies, pharmaceutical sponsors, and non-profit/academic medical centers. Its core commercial products are the GeneBrain® data analytics platform (with patented self-optimizing machine learning and 3D visualization) and the N of 1 Health Research Platform (a cloud-based SaaS for patient registries, ePRO, and observational studies). The majority of revenue is generated through federal IT services delivered under CIO-SP3, SPARC, and GSA Schedule contract vehicles using T&M, FFP, and CPFF task orders.

Product overview

Digital Infuzion offers a portfolio of proprietary products centered on two core platforms: GeneBrain® and the N of 1 Health Research Platform. GeneBrain® is a data analytics solution that applies patented self-optimizing machine learning algorithms and 3D visualization technology to complex biological and clinical data, enabling researchers to identify predictive biomarkers and discover patterns across large datasets. The N of 1 Health Research Platform is a cloud-based SaaS disease management and patient registry solution that integrates electronic patient-reported outcomes (ePRO), clinical data capture (EDC), and EMR interoperability to support observational research, rare disease registries, and patient-centric outcomes studies. The company also holds two foundational patents — Machine Learning Methods (US8386401) for automated predictive analytics and Visualizing Big Data (US8812274) for 3D data visualization — which underpin capabilities across both platforms. RegistryNXT! is a specialized configuration of the N of 1 platform built for pharmaceutical rare disease registries. Together, these products form an integrated ecosystem for translational research, from molecular data analysis to patient-level clinical outcomes.

Differentiator

Problem solved

Functional benefit

Brands

  • GeneBrain®: A data analytics solution that allows researchers and clinicians to gain at-a-glance insights into complex biological data using 3D visualizations and patented self-optimizing learning machines.
  • N of 1 Health Research Platform

Products and services

  • GeneBrain® A proprietary data analytics solution that models large volumes of complex biological data for monitoring, classification of samples, repository querying, biomarker identification, and hypothesis refinement and validation. Uses patented self-optimizing learning machines and 3D visualizations that make biological discoveries intuitive for biomedical researchers, clinical scientists, and pharmaceutical sponsors.
  • N of 1 Health Research Platform A real-time, patient-centric, web-based, mobile-friendly SaaS disease management and analytics platform for observational studies and patient registries. Features include electronic patient reported outcomes (ePRO), EDC and EMR integration, patient registry capabilities, GDPR/GCP/21 CFR Part 11/HIPAA compliance, and integration with wearables and biometric devices. Customers include pharmaceutical companies, biotech firms, patient advocacy groups, and academic organizations in the rare disease domain.
  • RegistryNXT! Platform A specialized implementation of the N of 1 Health Research Platform for managing rare disease registries, including for Sanofi Genzyme. Features CDISC-compliant data interchange, integration with Medidata's RAVE, role-based disease management, and regulatory reporting capabilities for pharmaceutical sponsors.

Quantifiable outcome

  • N of 1 Platform achieves 94%+ predictive accuracy in muscle tissue analysis using GeneBrain®
  • +4 more outcomes

Companies that use Digital Infuzion

Customer profile

Named customers24 records

Segments5 records

Ideal customer profiles3 records

Digital Infuzion technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability13 records

Feature4 records

Digital Infuzion partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core, minor and strategic.

  • INDUS CorporationcoreStrategic or Co-development Partner · 1 January 2012INDUS Corporation is the lead and contract holder for the CIO-SP3 Large Business GWAC through the HIITS CTA. Digital Infuzion is a strategic partner in this Contractor Team Arrangement fulfilling NITAAC's vision for CIO-SP3 GWAC serving NIH and all federal agencies.
  • Armedia, LLCcoreStrategic or Co-development Partner · 1 January 2012Armedia participates as CTA partner in both CIO-SP3 Large Business (HIITS CTA with INDUS) and CIO-SP3 8(a) Business (CIO Source CTA with Digital Infuzion). Armedia provides technology integration and data management capabilities for federal health IT contracts.
  • Aspire InformaticsminorOthers8(a) Joint Venture partner in Digital Infuzion's Mentor-Protégé Program. Aspire Informatics participates as a protégé organization benefiting from Digital Infuzion's domain expertise, business reputation, and resources.
  • Digital EdgeminorOthersWOSB (Women-Owned Small Business) Joint Venture partner in Digital Infuzion's Mentor-Protégé Program. Digital Edge participates as a protégé gaining access to Digital Infuzion's corporate capabilities while expanding market reach.
  • Tera FuzionminorOthersSDVOSB (Service-Disabled Veteran-Owned Small Business) Joint Venture partner in Digital Infuzion's Mentor-Protégé Program. Tera Fuzion collaborates with Digital Infuzion on federal contracting opportunities.
  • Carson AssociatesminorStrategic or Co-development PartnerCarson Associates participates as CTA partner in Digital Infuzion's CIO Source™ arrangement for CIO-SP3 8(a) Business GWAC, providing specialized technical capabilities for federal contracting engagements.
  • Partner EcosystemcoreChannel Partner/ Reseller/ DistributorDigital Infuzion maintains a diverse partner ecosystem of small businesses to large organizations with well-known brands to address complex Cloud services, cybersecurity, and data analytics challenges. Partners are assembled per customer requirement to deliver modern transformative solutions.
  • CDISC (Clinical Data Interchange Standards Consortium)strategicStrategic or Co-development PartnerDigital Infuzion serves on the CDISC Industry Advisory Board. The company helps standards organizations do their work by building web-based collaboration environments and providing services to enhance CDISC's business and data management activities. CDISC membership supports the company's healthcare data standardization mission.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Digital Infuzion competitors and assessment

Company assessment

Broad incumbents

  • IQVIA: Global clinical research services and technology vendor (formerly QuintilesIMS) competing head-to-head with DIFZ's N of 1 platform in rare disease registries, EDC, ePRO, and RWE/observational studies. Much larger commercial pharma focus and global footprint, but a frequent competitor and partner on registry initiatives.
  • Booz Allen Hamilton: Large public consulting firm with a major federal health IT practice (NIH, HHS, CMS, FDA) including health analytics, biosurveillance, and clinical research informatics. Competes with DIFZ on CIO-SP3 task orders and similar large federal health IT procurements but at vastly larger scale and broader capability footprint.
  • ICF International: Public consulting firm providing digital transformation, health analytics, and IT modernization to HHS, CMS, NIH, and CDC. Competes on overlapping federal health IT/RWE/biostatistics task orders with DIFZ but at significantly larger scale and broader commercial/government portfolio.
  • Leidos: Large public systems integrator with a substantial federal health and life sciences practice (NIH, CMS, FDA, DoD health) offering informatics, clinical research support, and biosurveillance. Competes with DIFZ on CIO-SP3 and SPARC task orders at a vastly larger scale.

Direct peers

  • Emmes Group: Private clinical research and biostatistics services organization serving NIH institutes (NIAID, NCI, NEI), FDA, and biopharma with patient registries, EDC, and data coordination. Highly comparable: similar size, biomedical research focus, founder-friendly federal culture, and DIFZ's CHRO Jennifer Fairfax previously served as CHRO at Emmes.
  • NORC at the University of Chicago: Non-profit research organization with strong federal health research IT practice including data coordination centers, biostatistics, and survey research for NIH, CMS, and HHS. Closely comparable by mission, federal health research focus, and clinical research informatics service mix (DIFZ is even mentioned as a collaborator context).
  • DLH Holdings Corp: Public federal health and science IT services company of comparable size, providing digital transformation, clinical research support, and program management to NIH, CDC, DoD, and CMS. Directly comparable on contract vehicles, federal health focus, and biomedical informatics delivery model—DIFZ's CGO Davyd Chung previously served as VP at DLH.
  • Mathematica Policy Research: Non-profit research organization with deep federal health research and data analytics practice serving HHS, CMS, NIH, and patient advocacy groups. Comparable on research IT, observational studies, and survey/data coordination for federal health; overlapping on data standards work.
  • RTI International: Non-profit research institute with a large federal health research IT and biostatistics practice serving NIH, FDA, and global health agencies. Comparable in clinical research informatics, patient registries, and federal contracting model—DIFZ is a vendor to RTI for the PopGen typhoid vaccine study using GeneBrain®.

Emerging players

  • Quartz Bio (or Crucial Data Solutions / Clinical Ink): Specialty ePRO/EDC and clinical trial technology providers focused on rare disease registries and patient-centric studies. Comparable to N of 1 in product category, customer segment (biotech/non-profit disease foundations), and SaaS delivery model—representing real potential share competition in DIFZ's rare disease sweet spot.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Digital Infuzion social profiles

Digital presence

Digital Infuzion compliance and trust

Trust signal

Compliance9 records

Digital Infuzion financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Digital Infuzion leadership team

Management profile

Number of profiles

Profiles15 records

Digital Infuzion funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Digital Infuzion M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Digital Infuzion

What does Digital Infuzion do?

Digital Infuzion delivers clinical informatics services and proprietary software platforms to federal health agencies, defense agencies, pharmaceutical sponsors, and non-profit/academic medical centers. Its core commercial products are the GeneBrain® data analytics platform (with patented self-optimizing machine learning and 3D visualization) and the N of 1 Health Research Platform (a cloud-based SaaS for patient registries, ePRO, and observational studies). The majority of revenue is generated through federal IT services delivered under CIO-SP3, SPARC, and GSA Schedule contract vehicles using T&M, FFP, and CPFF task orders.

Is Digital Infuzion a public or private company?

Digital Infuzion is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Digital Infuzion founded?

Digital Infuzion was founded in 1999. It employs 101 to 250 people.

Where is Digital Infuzion based?

Digital Infuzion is headquartered in Rockville, United States, in the North America region.

How does Digital Infuzion make money?

Three revenue lines are on record. Federal Government IT Services are the primary driver. The others are commercial Healthcare IT Services and N of 1 Health Research Platform (SaaS).

Who are Digital Infuzion's main competitors?

Broad incumbents on record are IQVIA, Booz Allen Hamilton, ICF International and Leidos. Direct peers are Emmes Group, NORC at the University of Chicago, DLH Holdings Corp, Mathematica Policy Research and RTI International. Quartz Bio (or Crucial Data Solutions / Clinical Ink) is listed as an emerging player.

Does Digital Infuzion have an API?

No public API is recorded for Digital Infuzion.

What industry is Digital Infuzion in?

Digital Infuzion's product category is Clinical Research Informatics. Its primary akta.pro industry code is HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF), with a secondary code of HLACAOAJ, Site & Investigator Platforms (Site Payments, Feasibility, Activation). Its NAICS code is 5417 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PrwebDigital Infuzion, LLC Earns 2026 Great Place To Work Certification™Digital Infuzion, LLC earned its second consecutive Great Place To Work certification, based on employee feedback. 91% of respondents said it is a great place to work, three points above the 2026 U.S. Top 100 average. The company highlighted its commitment to employee experience and growth.PrwebDigital Infuzion, LLC Earns 2025 Great Place To Work Certification™Digital Infuzion, LLC has been Certified™ by Great Place To Work® for 2025, based on employee feedback where 87% of respondents reported it is a great place to work. The certification is earned through real-time employee feedback regarding workplace culture, distinguishing Digital Infuzion as a top company for employment. The firm, which provides life sciences and health research solutions to federal agencies including NIH, CMS, HRSA, USDA, and DHS, stated the recognition reflects its commitment to transparency, trust, and employee well-being.PR NewswireDigital Infuzion Selected to Develop the Statistical, Data Management, and Coordination Center (SDMCC) for NIAID's New Coordinated Approach to Develop a Universal Influenza VaccineDigital Infuzion was selected by the National Institute of Allergy and Infectious Diseases (NIAID) to develop the Statistical, Data Management, and Coordination Center for the Collaborative Influenza Vaccine Innovation Centers program. The coordinating center will collaborate with other CIVICs units to establish data standards, design clinical trials, and manage experimental data sharing with an initial award value of approximately $1.4 million. Partners The Emmes Company, LLC, and Gryphon Scientific, LLC are also involved in this strategic endeavor to develop broadly protective influenza vaccines.PR NewswireRecent Federal Leader and Strategist Nancy Nurthen Named Digital Infuzion's VP, Digital Health Strategy & InnovationDigital Infuzion, Inc. announced the appointment of Nancy Nurthen as Vice President of Digital Health Strategy & Innovation. Nurthen brings over 11 years of experience from federal agencies, including HHS and ASPR, to lead the company's digital health initiatives. This strategic hire aims to leverage her expertise in bioinformatics and health surveillance to enhance the firm's service offerings.